The DOI matches its Crossref record; 15 of the 15 references it cites were found in a registry or an index.
Metal‐Catalyzed Disruption of Membrane Protein and Lipid Signaling in the Pathogenesis of Neurodegenerative Disorders
Abstract
A bstract: Membrane lipid peroxidation and oxidative modification of various membrane and associated proteins (e.g., receptors, ion transporters and channels, and signal transduction and cytoskeletal proteins) occur in a range of neurodegenerative disorders. This membrane‐associated oxidative stress (MAOS) is promoted by redox‐active metals, most notably iron and copper. The mechanisms whereby different genetic and environmental factors initiate MAOS in specific neurological disorders are being elucidated. In Alzheimer's disease (AD), the amyloid β‐peptide generates reactive oxygen species and induces MAOS, resulting in disruption of cellular calcium homeostasis. In Parkinson's disease (PD), mitochondrial toxins and perturbed ubiquitin‐dependent proteolysis may impair ATP production and increase oxyradical production and MAOS. The inheritance of polyglutamine‐expanded huntingtin may promote neuronal degeneration in Huntington's disease (HD), in part, by increasing MAOS. Increased MAOS occurs in amyotrophic lateral sclerosis (ALS) as the result of genetic abnormalities (e.g., Cu/Zn‐superoxide dismutase mutations) or exposure to environmental toxins. Levels of iron are increased in vulnerable neuronal populations in AD and PD, and dietary and pharmacological manipulations of iron and copper modify the course of the disease in mouse models of AD and PD in ways that suggest a role for these metals in disease pathogenesis. An increasing number of pharmacological and dietary interventions are being identified that can suppress MAOS and neuronal damage and improve functional outcome in animal models of AD, PD, HD, and ALS. Novel preventative and therapeutic approaches for neurodegenerative disorders are emerging from basic research on the molecular and cellular actions of metals and MAOS in neural cells.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Apoptosis in neurodegenerative disorders
Mattson, M. P. (2000) · Nature Reviews Molecular Cell Biology · doi:10.1038/35040009 · Cited by 1,605
Self-citationCherny, R. A., Atwood, C. S., Xilinas, M. E., Gray, D. N., Jones, W. D., McLean, C. A., Barnham, K. J., Volitakis, I., Fraser, F. W., Kim, Y.-S., et al. (2001) · Neuron · doi:10.1016/s0896-6273(01)00317-8 · Cited by 1,447
Hensley, K., Carney, J. M., Mattson, M. P., Aksenova, M., Harris, M., Wu, J. F., Floyd, R. A., & Butterfield, D. A. (1994) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.91.8.3270 · Cited by 1,086
Self-citationEffects of Coenzyme Q10 in Early Parkinson Disease: Evidence of Slowing of the Functional Decline
Shults, C. W. (2002) · Archives of Neurology · doi:10.1001/archneur.59.10.1541 · Cited by 984
Immunohistochemical detection of 4-hydroxynonenal protein adducts in Parkinson disease.
Yoritaka, A., Hattori, N., Uchida, K., Tanaka, M., Stadtman, E. R., & Mizuno, Y. (1996) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.93.7.2696 · Cited by 981
Keller, J. N., Kindy, M. S., Holtsberg, F. W., St. Clair, D. K., Yen, H.-C., Germeyer, A., Steiner, S. M., Bruce-Keller, A. J., Hutchins, J. B., & Mattson, M. P. (1998) · The Journal of Neuroscience · doi:10.1523/jneurosci.18-02-00687.1998 · Cited by 863
Self-citationKruman, I. I., Culmsee, C., Chan, S. L., Kruman, Y., Guo, Z., Penix, L., & Mattson, M. P. (2000) · The Journal of Neuroscience · doi:10.1523/jneurosci.20-18-06920.2000 · Cited by 784
Self-citationMark, R. J., Pang, Z., Geddes, J. W., Uchida, K., & Mattson, M. P. (1997) · The Journal of Neuroscience · doi:10.1523/jneurosci.17-03-01046.1997 · Cited by 551
Self-citationDuan, W., Guo, Z., Jiang, H., Ware, M., Li, X.-J., & Mattson, M. P. (2003) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0536856100 · Cited by 428
Self-citationMattson, M. P. (1998) · Trends in Neurosciences · doi:10.1016/s0166-2236(97)01188-0 · Cited by 344
Self-citation
Cited by
Uttara, B., Singh, A., Zamboni, P., & Mahajan, R. (2009) · Current Neuropharmacology · doi:10.2174/157015909787602823 · Cited by 3,378
“Neurodegeneration have been speculated to be interplay of a number of factors including environmental and genetic predisposition but redox metal abuse occupies central role as most of symptoms stems out from abnormal metal metabolism [53].”
BackgroundMulti-target-Directed Ligands To Combat Neurodegenerative Diseases
Cavalli, A., Bolognesi, M. L., Minarini, A., Rosini, M., Tumiatti, V., Recanatini, M., & Melchiorre, C. (2008) · Journal of Medicinal Chemistry · doi:10.1021/jm7009364 · Cited by 1,152
Kell, D. B. (2009) · BMC Medical Genomics · doi:10.1186/1755-8794-2-2 · Cited by 554
A delicate balance: Iron metabolism and diseases of the brain
Hare, D., Ayton, S., Bush, A., & Lei, P. (2013) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2013.00034 · Cited by 443
Oxidative stress and mitochondrial dysfunction in neurodegenerative diseases
Trushina, E., & McMurray, C. T. (2007) · Neuroscience · doi:10.1016/j.neuroscience.2006.10.056 · Cited by 439
Multi-functional drugs for various CNS targets in the treatment of neurodegenerative disorders
Youdim, M. B. H., & Buccafusco, J. J. (2005) · Trends in Pharmacological Sciences · doi:10.1016/j.tips.2004.11.007 · Cited by 380
Kell, D. B. (2010) · Archives of Toxicology · doi:10.1007/s00204-010-0577-x · Cited by 361
Alzheimer’s disease: pathological mechanisms and the beneficial role of melatonin
Rosales‐Corral, S. A., Acuña‐Castroviejo, D., Coto‐Montes, A., Boga, J. A., Manchester, L. C., Fuentes‐Broto, L., Korkmaz, A., Ma, S., Tan, D. X., & Reiter, R. J. (2012) · Journal of Pineal Research · doi:10.1111/j.1600-079x.2011.00937.x · Cited by 294
Mandel, S., Amit, T., Reznichenko, L., Weinreb, O., & Youdim, M. B. H. (2006) · Molecular Nutrition & Food Research · doi:10.1002/mnfr.200500156 · Cited by 291
Copper and Oxidative Stress in the Pathogenesis of Alzheimer’s Disease
Eskici, G., & Axelsen, P. H. (2012) · Biochemistry · doi:10.1021/bi3006169 · Cited by 290
Iron and Alzheimer’s Disease: An Update on Emerging Mechanisms
Lane, D. J. R., Ayton, S., & Bush, A. I. (2018) · Journal of Alzheimer's Disease · doi:10.3233/jad-179944 · Cited by 276
Effects of electromagnetic fields exposure on the antioxidant defense system
Kivrak, E., Yurt, K., Kaplan, A., Alkan, I., & Altun, G. (2017) · Journal of Microscopy and Ultrastructure · doi:10.1016/j.jmau.2017.07.003 · Cited by 266
Nguyen, T., Hamby, A., & Massa, S. M. (2005) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0502177102 · Cited by 194
Amyotrophic Lateral Sclerosis: From Current Developments in the Laboratory to Clinical Implications
Cozzolino, M., Ferri, A., & Teresa Carrì, M. (2008) · Antioxidants & Redox Signaling · doi:10.1089/ars.2007.1760 · Cited by 156
Neuroprotective mechanisms of ayurvedic antidementia botanical Bacopa monniera
Dhanasekaran, M., Tharakan, B., Holcomb, L. A., Hitt, A. R., Young, K. A., & Manyam, B. V. (2007) · Phytotherapy Research · doi:10.1002/ptr.2195 · Cited by 148
Long-Term Intermittent Hypoxia
Veasey, S. C., Zhan, G., Fenik, P., & Pratico, D. (2004) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.200403-261oc · Cited by 91
Sultana, R., Reed, T., Perluigi, M., Coccia, R., Pierce, W. M., & Butterfield, D. A. (2007) · Journal of Cellular and Molecular Medicine · doi:10.1111/j.1582-4934.2007.00065.x · Cited by 87
Huntingtin inclusion bodies are iron‐dependent centers of oxidative events
Firdaus, W. J. J., Wyttenbach, A., Giuliano, P., Kretz‐Remy, C., Currie, R. W., & Arrigo, A. (2006) · The FEBS Journal · doi:10.1111/j.1742-4658.2006.05537.x · Cited by 71
Juranek, J. K., Daffu, G. K., Wojtkiewicz, J., Lacomis, D., Kofler, J., & Schmidt, A. M. (2015) · Frontiers in Cellular Neuroscience · doi:10.3389/fncel.2015.00485 · Cited by 66
Iron Pathophysiology in Alzheimer’s Diseases
Wang, T., Xu, S.-F., Fan, Y.-G., Li, L.-B., & Guo, C. (2019) · Advances in experimental medicine and biology · doi:10.1007/978-981-13-9589-5_5 · Cited by 64
Petri, S., Calingasan, N. Y., Alsaied, O. A., Wille, E., Kiaei, M., Friedman, J. E., Baranova, O., Chavez, J. C., & Beal, M. F. (2007) · Journal of Neurochemistry · doi:10.1111/j.1471-4159.2007.04604.x · Cited by 55
“Metal-associated oxidative stress is also a presumed pathomechanism in Parkinson’s and Huntington’s disease (Mattson 2004), and clioquinol showed neuroprotective effects in models of these diseases (Kaur et al. 2003).”
BackgroundZheng, H., Youdim, M. B. H., Weiner, L. M., & Fridkin, M. (2005) · Biochemical Pharmacology · doi:10.1016/j.bcp.2005.09.003 · Cited by 53
Hague, T., Andrews, P. L. R., Barker, J., & Naughton, D. P. (2006) · Behavioural Pharmacology · doi:10.1097/00008877-200609000-00008 · Cited by 12
Metadata
- Authors
- MATTSON, M. P.
- Venue
- Annals of the New York Academy of Sciences
- Publisher
- Wiley
- Published
- 2004-03
- Volume
- 1012
- Issue
- 1
- Pages
- 37-50
- ISSN
- 0077-8923 (ISSN-L)
- 1749-6632
- OpenAlex
- W2059963027
- Cited by
- 164
- References
- 15
- FWCI
- 8.36
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.